Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Chronic Lymphocytic Leukemia
Related studies linked through entity extraction aliases.
Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Status
- RECRUITING
- Phase
- PHASE1
Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL
- Status
- WITHDRAWN
- Phase
- PHASE1
Observational Study of Ibrutinib Use in CLL
- Status
- UNKNOWN
- Phase
- N/A
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
- Status
- TERMINATED
- Phase
- PHASE2
Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
- Status
- TERMINATED
- Phase
- PHASE1
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC Study
- Status
- COMPLETED
- Phase
- N/A
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Gazyva Infusion Reaction Investigation
- Status
- UNKNOWN
- Phase
- N/A
The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With Ibrutinib
- Status
- COMPLETED
- Phase
- N/A
Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
- Status
- COMPLETED
- Phase
- PHASE1
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
- Status
- TERMINATED
- Phase
- PHASE2
Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
- Status
- RECRUITING
- Phase
- N/A